Caught Between a Rock and a Hard Place: Comanagement of Neov -

Thank you for attending. The posttest will not be available immediately. You will receive an email with a link to obtain credit within 48 hours of the program's completion.
Note for Allied Ophthalmic Personnel: You must view the course in its entirety, whether attending in person or virtually. IJCAHPO guidelines dictate that CE credit for a course will be denied to individuals who miss more than 25% of that course. Attendees who meet the required instructional time and passing grade established by IJHCAPO will receive an email with a link to obtain credit within 48 hours of the program's completion.

Scroll back to top

Details

Overview
In 2023, two complement inhibitors (CIs) were approved by the FDA for the treatment of geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). These first-in-class agents have generated enthusiasm among retina specialists, however, there is also confusion and wariness about the patients who would most benefit from their use and concerns about clinic workflow and cotreatment for neovascular AMD and GA.
Program Chair Michael Singer, MD, will join Neil Bressler, MD; Carl J. Danzig, MD, FASRS; and Nathan Steinle, MD, for a panel discussion to address these issues and much more!
This educational activity is designed for retina specialists involved in the care of patients with geographic atrophy (GA) as well as those involved in managed care.

This activity is supported by an independent educational grant from Astellas.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Extrapolate the prevalence of patients who have or may develop both neovascular age-related macular degeneration (nAMD) and geographic atrophy (GA)
- Propose a scientific rationale and clinical management approach for the cotreatment of nAMD and GA
- Interpret clinical trial data for anticomplement therapies for GA
- Examine available clinical evidence whereby both anticomplement and anti-VEGF treatments were delivered for the treatment of AMD
- Assess patient characteristics and safety/visual data in cotreatment studies to determine outcomes with anti-complement and anti-VEGF therapies
- Discuss workflow, logistical, and insurance/reimbursement issues that may affect the cotreatment of nAMD and GA
Accreditation
Target Audience
This educational activity is designed for retina specialists involved in the care of patients with geographic atrophy (GA) as well as those involved in managed care.

Accreditation & Designation Statements
This educational activity is jointly provided by Evolve Medical Education and AXIS Medical Education.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and AXIS Medical Education.
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This application-based activity is approved for 1.5 contact hours of continuing pharmacy education JA4008106-9999-24-051-L01-P.

This Live Stream program has been accredited for 1.5 IJCAHPO CE credits. CE credit for a course will be denied to individuals who miss more than 25% of that course.
This program is not sponsored by IJCAHPO; it is only reviewed for compliance with IJCAHPO standards and criteria and awarded continuing education credit accordingly; therefore, IJCAHPO cannot predict the effectiveness of the program or assure its quality in substance and presentation.

To obtain your CME/CE credit, you will need to log into your Evolve Medical Education account to complete the pretest before the presentation begins.
Within 48 hours of the program's completion, you will receive an email with a link to take the posttest, complete the evaluation, and claim your credit.

Note for Allied Ophthalmic Personnel: You must view the course in its entirety, whether attending in person or virtually.
IJCAHPO guidelines dictate that CE credit for a course will be denied to individuals who miss more than 25% of that course. Only those students who receive a passing grade (75% or higher) on the post-test/quiz and complete the program evaluation may receive IJCAHPO CE credit.
Attendees who meet the required instructional time and passing grade established by IJHCAPO will receive an email with a link to obtain credit within 48 hours of the program's completion.

The posttest will not be available immediately. It will be accessible once the link has been emailed to you, which will be within 48 hours of the conclusion of the symposium.
Participation Method
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Faculty and Disclosures
Michael Singer, MD
Clinical Professor
University of Texas Health Science Center
San Antonio, TX

Neil Bressler, MD
Professor of Ophthalmology
Johns Hopkins School of Medicine
Baltimore, MD

Carl J. Danzig, MD, FASRS
Director of Vitreoretinal Services and Retina Clinical Research
Rand Eye Institute
Deerfield Beach, FL
Affiliate Assistant Professor of Clinical Biomedical Science
Florida Atlantic University - Charles E. Schmidt College of Medicine
Boca Raton, FL

Nathan Steinle, MD
California Retina Consultants
Santa Barbara, CA

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Michael Singer, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: AbbVie, Apellis, Astellas, Bausch + Lomb, Biogen, Coherus Biosciences, EyePoint Pharmaceuticals, Genentech, Ocular Therapeutix, and Regeneron. Grant/Research Support: Genentech. Speaker's Bureau: Alimera Sciences, Apellis, and Bausch + Lomb.
Neil Bressler, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Chair: Emmes Data and Safety Monitoring Committee for the NEI Intramural Program and FDA Ophthalmic Devices Panel. Consultant: EDIC/DCCT Oversight Safety Monitoring Board (NIDDK). Editor-in-Chief: JAMA Ophthalmology. Grant/Research Support: Bayer, Biogen, Boehringer Ingelheim, Genentech, Regeneron, and Samsung Bioepis.
Carl J. Danzig, MD, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Adverum Biotechnologies, Alimera Sciences, Galimedix Therapeutics, Genentech, Iveric Bio/Astellas, Kodiak Sciences, Novartis, Ocuphire Pharma, Opthea, Regeneron, Regenxbio, and Roche. Grant/Research Support: 4DMT, Adverum Biotechnologies, Alexion, Aviceda, Bayer, Cognition, Curacle, EyeBio, Genentech, Gyroscope Therapeutics, Iveric Bio/Astellas, Kodiak Sciences, Novartis, Oculis, Regeneron, Regenxbio, Rezolute, Roche, and Unity Biotechnology. Speaker's Bureau: Genentech and Iveric Bio/Astellas.
Nathan Steinle, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Amgen, Apellis, Biogen, Carl Zeiss Meditec, Genentech, Novartis, Regeneron, and Zeiss. Grant/Research Support: Genentech, Novartis, Regeneron, and Regenxbio. Speaker's Bureau: Alimera Sciences, Apellis, Bausch + Lomb, Genentech, Novartis, and Regeneron. Shareholder: Regeneron and Vortex Surgical.
The Evolve and AXIS staff, planners and peer reviewers have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, AXIS, or Astellas.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 09/13/2024

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Title

Share on ReachMD